CWC
KURA icon

Carolinas Wealth Consulting’s Kura Oncology KURA Stock Holding History

Carolinas Wealth Consulting’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-37
Closed -$1K – 956
2020
Q3 		$1K Buy
+37
New +$817 ﹤0.01% 843

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Carolinas Wealth Consulting's KURA Position: Q4 2020 in Review

Carolinas Wealth Consulting sold out of Kura Oncology (KURA) in Q4 2020, closing a stake of 37 shares — an estimated $1K sold.

Carolinas Wealth Consulting first reported a position in KURA in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 198 funds tracked by Wall St. Rank hold KURA as of Q4 2020.

  • Carolinas Wealth Consulting reported no remaining Kura Oncology position as of Q4 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 37 Kura Oncology shares in Q4 2020, an estimated $1K.
  • Carolinas Wealth Consulting first reported a position in Kura Oncology in Q3 2020 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Kura Oncology position peaked at $1K in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2020, filed 16 Feb 2021.